Department of Surgery, Nowon Eulji Medical Center, Eulji University College of Medicine, Seoul, Republic of Korea.
Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University, College of Medicine, Seoul, Republic of Korea.
Int J Surg. 2018 Jan;49:10-15. doi: 10.1016/j.ijsu.2017.11.038. Epub 2017 Dec 1.
The aim of this study is to estimate prognostic factors predicting survival in patients with incurable stage IV colorectal cancer (CRC), who underwent palliative primary tumor resection (PTR) with chemotherapy.
We retrospectively performed an analysis using clinicopathological parameters of 103 patients with incurable stage IV CRC, who underwent palliative PTR with chemotherapy between 2006 and 2010. Prognostic factors associated with overall survival (OS) were evaluated by univariate and multivariate analyses.
The median follow-up time was 17.5 months (range 2.4-60.5) for the total cohort (n = 103). There were five independent factors related to OS in univariate analysis (body mass index, tumor differentiation, pT, pN stage and local clearance of the primary tumor). A multivariate analysis revealed that pT, pN and local clearance of the primary tumor were prognostic factors related to OS. Median survival months (95% CI) were pT1, 2, 3: 21.5 (16.23-26.77) months vs. pT4: 13.73 (9.94-17.53) months, pN-: 29.7 (22.55-35.99) months vs. pN+: 17.1 (15.0-19.41) months and R0: 18.57 (16.65-20.48) months vs. R1, 2: 12.43 (9.95-14.91) months.
Locally advanced primary tumor (high pT stage, positive regional lymph node, and local residual primary tumor) was associated with poorer OS in incurable stage IV CRC patients, who underwent palliative PTR with chemotherapy. The PTR appears to result in better OS in patients with a primary tumor that is not locally advanced.
本研究旨在评估姑息性原发肿瘤切除术(PTR)联合化疗治疗不可治愈的 IV 期结直肠癌(CRC)患者的生存预后相关因素。
我们回顾性分析了 2006 年至 2010 年间 103 例接受姑息性 PTR 联合化疗的不可治愈 IV 期 CRC 患者的临床病理参数。通过单因素和多因素分析评估与总生存期(OS)相关的预后因素。
全队列(n=103)的中位随访时间为 17.5 个月(范围 2.4-60.5)。单因素分析中有 5 个与 OS 相关的独立因素(体质指数、肿瘤分化、pT、pN 分期和原发肿瘤局部清除)。多因素分析显示,pT、pN 和原发肿瘤局部清除是与 OS 相关的预后因素。中位生存月数(95%CI)为 pT1、2、3:21.5(16.23-26.77)个月 vs. pT4:13.73(9.94-17.53)个月,pN-:29.7(22.55-35.99)个月 vs. pN+:17.1(15.0-19.41)个月,R0:18.57(16.65-20.48)个月 vs. R1、2:12.43(9.95-14.91)个月。
不可治愈的 IV 期 CRC 患者姑息性 PTR 联合化疗后,局部进展期原发肿瘤(高 pT 分期、阳性区域淋巴结和局部残留原发肿瘤)与较差的 OS 相关。对于局部未进展的原发肿瘤患者,PTR 似乎能带来更好的 OS。